Loading
A phase 3 trial of Inavolisib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer is a phase 3 interventional study registered as NCT06790693 by Hoffmann-La Roche, with 450 participants planned, started 2025-04-09 and due to reach its primary completion in 2032-01-31. Interventions recorded: Inavolisib, Placebo, CDK4/6i and Letrozole.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, PI3K, AKT and mTOR inhibitors, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.